Cancer Does Not Pause for a Poorly Made Wig

Why Clinical Readiness Is the Entire Job in Oncology Hair Care

Cancer does not pause for a poorly made wig. When a woman walks into a clinical fitting in the middle of chemotherapy, her scalp is not the scalp she had six weeks ago. Her skin barrier is compromised. Her immune defenses may be suppressed depending on her regimen, blood counts, timing, and overall medical status. Her tissue is reactive, often inflamed, and frequently painful to the touch. She is not shopping. She is surviving.

The wig she leaves with has to meet her where she is. Anything less is not a fitting. It is a liability.

“Clinical readiness is not optional. It is the entire job.”

The Scalp Under Treatment Is a Different Scalp

Chemotherapy-induced alopecia is one of the most visible side effects of cancer treatment, and one of the most psychologically distressing. Research consistently identifies hair loss as among the most feared consequences of chemotherapy, with reported prevalence as high as 47 to 65 percent of patients depending on regimen, and a substantial subset experiencing persistent or permanent alopecia after treatment ends.

Beyond the visible loss, the underlying physiology changes. Cytotoxic agents damage rapidly dividing cells in the hair matrix, but they also affect epidermal turnover, sebaceous function, and the cutaneous microbiome. Patients commonly present with dryness, increased sensitivity, scaling, and reduced barrier integrity. Radiation therapy adds another layer, producing acute and late skin reactions including erythema, desquamation, fibrosis, and chronic dermatitis in the treated field.

These are not cosmetic considerations. They are clinical realities that determine which materials, construction methods, and attachment systems are safe to place on the head.

What Clinical Readiness Actually Requires

Clinical readiness begins long before the client arrives. It is built into the prosthesis itself, into the training of the maker, and into the protocols of the practice.

•       Breathable foundations. Cap construction should support heat release, moisture management, and reduced friction. Occlusion increases scalp temperature and humidity, both of which contribute to microbial overgrowth and irritation.

•       Hypoallergenic materials. Many commercial wigs use latex, dyes, and adhesives that can trigger allergic contact dermatitis on chemotherapy-sensitized skin. Medical-grade silicones, selected polyurethane components, and tested mesh may be appropriate when chosen according to scalp condition, treatment history, sensitivity, and wear schedule. Untested materials are not.

•       Adaptive sizing. Scalp volume and contour can shift during treatment due to edema, weight changes, and tissue response. A prosthesis should allow reasonable adjustment as scalp contour, tissue sensitivity, and fit needs change during treatment.

•       Attachment safety. Adhesives, tapes, and tension-based systems must respect port sites, radiation fields, surgical incisions, and any active dermatologic involvement. The wrong attachment can cause folliculitis, traction injury, or breakdown of fragile skin.

•       Clinical communication. The provider must be able to coordinate with the patient’s oncology team, document the medical necessity, and supply the codes and letters required by insurance and the VA.

Where the Industry Has Failed

For decades, the wig industry has sold aesthetics to a medical population without the training to serve them safely. The consequences show up in our chairs and in the published literature. Contact dermatitis from unidentified adhesives. Folliculitis under occlusive caps. Traction damage on hair that was already attempting to regrow. Patients who paid thousands of dollars and still felt unseen, uneducated, and undertreated.

Many retail wig sales happen without a documented scalp assessment, medical history review, or written care protocol. There is no industry-wide credential that requires training in trichology, oncology workflows, or dermatologic safety before a maker can sell a wig to a cancer patient. That gap is not a marketing problem. It is a patient safety problem.

The Standard a Cranial Prosthesis Should Meet

A cranial prosthesis built for a medically compromised scalp is not a wig with a different label. It is a different product, made by different hands, governed by different standards.

It is custom fitted to the individual head, often from a mold or precise measurement protocol. The base materials are selected for skin compatibility, sensitivity, and intended wear schedule. The hair, whether human or fiber, is ventilated or constructed in a way that distributes weight evenly and avoids point loading. Documentation may include the appropriate HCPCS code recognized by the payer, commonly A9282, Wig, any type, each, which many carriers accept when the item is described as a cranial prosthesis or medical hair prosthesis. Some older reimbursement materials reference S8095, which is widely reported as a deleted code, so providers should verify current payer-specific requirements before submitting claims. A letter or prescription of medical necessity is often required by private carriers, and VA coverage should be verified through the patient’s VA health care team or prosthetic services pathway.

This is the standard we teach inside HIASTI. It is the standard we publish in the Hair and Wig Science Series. And it is the standard every patient navigating cancer treatment has the right to expect.

Why This Matters Beyond the Fitting Room

Hair loss during cancer treatment is not vanity. Multiple studies have documented its impact on body image, treatment adherence, social withdrawal, and quality of life. Patients who feel visibly altered are more likely to isolate, more likely to delay return to work, and more likely to report depressive symptoms. A well-made prosthesis does not cure cancer. It does give a patient back a measure of agency over how she meets the world during the hardest year of her life.

That is clinical work. It is also human work. The two cannot be separated.

Cancer will not wait. Neither should the quality of her care.

What Professionals Can Do Now

If you serve clients with cancer in any capacity, whether as a stylist, a wig provider, a cranial prosthesis specialist, an oncology nurse, or a patient navigator, raise the standard you operate under.

•       Get trained in trichology, oncology care basics, and dermatologic safety before you accept another oncology client.

•       Build a referral relationship with a maker who specializes in medically compromised scalps, and refer when a case exceeds your scope.

•       Document every fitting. Photograph the scalp at intake. Record materials used, attachment method, and client-reported sensitivity.

•       Learn the insurance pathways. HCPCS A9282 with payer-specific verification, VA prosthetic services, FSA and HSA reimbursement, and private carrier letters of medical necessity are not optional skills for this work.

The patient does not have time to wait for the industry to catch up. She is in treatment now. The standard has to be ready for her when she arrives.

Clinical readiness is not optional. It is the entire job.

Continue the Clinical Education

For professionals who want to understand the science behind safer foundation selection, scalp assessment, material choice, and long-term wear planning, these principles are explored in greater depth in The Science of Wig Foundations: A Clinical Guide to Scalp Health, part of the Hair and Wig Science Series by Egypt Lawson.

This text was written for wig makers, cranial prosthesis specialists, hair replacement professionals, and educators who serve clients with medically sensitive scalps. It explains how foundation design, attachment methods, ventilation choices, and scalp health considerations work together when a wig is no longer simply cosmetic, but part of a client’s daily comfort, dignity, and care experience.

To learn more or order the book,

Mastering the Art and Science of Hair 🧬 Foundations

From$150.00

Buy Now

References

Trueb, R. M. (2009). Chemotherapy-induced alopecia. Seminars in Cutaneous Medicine and Surgery, 28(1), 11 to 14. https://pubmed.ncbi.nlm.nih.gov/19341937/

Rossi, A., Fortuna, M. C., Caro, G., Pranteda, G., Garelli, V., Pompili, U., and Carlesimo, M. (2017). Chemotherapy-induced alopecia management: clinical experience and practical advice. Journal of Cosmetic Dermatology, 16(4), 537 to 541. https://pubmed.ncbi.nlm.nih.gov/28169502/

Lemieux, J., Maunsell, E., and Provencher, L. (2008). Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psycho-Oncology, 17(4), 317 to 328. https://pubmed.ncbi.nlm.nih.gov/17721909/

Choi, E. K., Kim, I. R., Chang, O., Kang, D., Nam, S. J., Lee, J. E., Lee, S. K., Im, Y. H., Park, Y. H., Yang, J. H., and Cho, J. (2014). Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psycho-Oncology, 23(10), 1103 to 1110. https://pubmed.ncbi.nlm.nih.gov/24664939/

Freites-Martinez, A., Shapiro, J., Goldfarb, S., Nangia, J., Jimenez, J. J., Paus, R., and Lacouture, M. E. (2019). Hair disorders in patients with cancer. Journal of the American Academy of Dermatology, 80(5), 1179 to 1196. https://pubmed.ncbi.nlm.nih.gov/29660422/

Hesketh, P. J., Batchelor, D., Golant, M., Lyman, G. H., Rhodes, N., and Yardley, D. (2004). Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Supportive Care in Cancer, 12(8), 543 to 549. https://pubmed.ncbi.nlm.nih.gov/15221580/

Centers for Medicare and Medicaid Services. HCPCS Level II Code A9282, Wig, any type, each. CMS HCPCS Quarterly Update. https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system

U.S. Department of Veterans Affairs, Veterans Health Administration. Prosthetic and Sensory Aids Service, cranial prosthesis benefit guidance. https://www.prosthetics.va.gov/

American Cancer Society. Hair loss (alopecia) and cancer treatment. https://www.cancer.org/cancer/managing-cancer/side-effects/hair-skin-nails/hair-loss.html

National Cancer Institute. Hair loss (alopecia) and cancer treatment, PDQ supportive care. https://www.cancer.gov/about-cancer/treatment/side-effects/hair-loss

©2026 Hairline Illusions™ All rights reserved